BACKGROUND Patients with atrial fibrillation (AF) have an increased risk of cognitive decline, potentially resulting
T he prevalence of atrial fibrillation (AF) in the general population is increasing rapidly (1) . Patients with AF are at high risk of adverse events.
Although the relationships of AF with death, stroke, and congestive heart failure have been known for many years (2, 3) , more recent evidence suggests that patients with AF also face an increased risk of cognitive dysfunction and dementia (4, 5) . This growing awareness is reflected by a recent publication of an international expert consensus paper on this topic (6) .
Meta-analyses suggest that part of the association between AF and dementia is explained by the higher stroke risk among patients with AF, but the risk of dementia was also increased in patients with AF but without a clinical history of stroke (5) . Clinically unrecognized (silent) cerebral infarcts, microbleeds, or other brain lesions may explain this association, but systematic investigations in patients with AF are currently lacking. Microbleeds are of particular interest because patients with AF usually need lifelong oral anticoagulation for stroke prevention (7) . Although prior studies did not show a consistent trend of more microbleeds among patients using oral anticoagulation, the use of this therapy among patients with a significant burden of microbleeds remains controversial (8) (9) (10) .
The aim of the current study was to assess the relationships of clinically known and unknown (silent) vascular brain lesions detected on brain magnetic resonance imaging (MRI) with cognitive function in a large sample of patients with AF. We focused on large infarcts and infarcts involving the brain cortex, which may originate from embolic mechanisms and as such represent AF-related sequelae. We also considered imaging markers of cerebral small vessel disease, which share vascular risk factors with AF, including white matter disease, small noncortical infarcts Switzerland. The detailed methodology has been described previously (13) . Patients were eligible for Swiss-AF if they had a history of documented AF and if they were 65 years old or older. In addition, we aimed to enroll 10% to 15% of patients between 45
and 65 years of age to assess the effects of AF on individuals in the active workforce. We excluded patients with secondary forms of AF and patients who were unable to provide informed consent. Patients with an acute illness within the last 4 weeks could be enrolled only once the acute episode had resolved. 
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RESULTS
Baseline characteristics are shown in 
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with or without silent SNCI (25. Values are mean AE SD or n (%). *The p value compares patients with and without a history of stroke or TIA; p values were obtained from Wilcoxon rank-sum tests for continuous variables and chi-square tests for categorical variables. †Basic education: #6 yrs (less than compulsory education curriculum); middle education: 6 to #12 yrs (high school or similar); advanced education: $12 yrs (college or university degree).
CHA2DS2-VASc ¼ congestive heart failure, hypertension, age $75 yrs (2 points), diabetes, prior stroke or TIA or thromboembolism (2 points), vascular disease, age 65 to 74 yrs, female sex; TIA ¼ transient ischemic attack. TIA ¼ transient ischemic attack. Table 3 ).
The same subgroups were assessed for differences in brain lesion parameters (Online Table 12 ). Larger LNCCI volumes were observed in patients with permanent AF, higher CHA 2 DS 2 -VASc scores, and those with a history of stroke, hypertension, or diabetes.
Oral anticoagulation with either direct oral anticoagulant agents or vitamin K antagonists was not associated with a higher microbleed count compared with no anticoagulation. Higher CHA 2 DS 2 -VASc scores were associated with significantly higher infarct and white matter lesion volumes, but lower microbleed counts (Online Table 12 ). Comparing the prevalence of brain MRI lesions across studies is difficult because of differences in Results are from linear mixed effects models, taking into account the effect of study center. Vascular brain lesion volumes are centered on the mean natural-log transformed volumes. Models include, for each damage type, an indicator of the presence of the damage alongside the measurement of volume or, for microbleeds, count. Multivariable models are adjusted for age, sex, history of hypertension, smoking status, history of diabetes, body mass index, atrial fibrillation type, education level, oral anticoagulation (yes, no). Coefficients of all covariates are presented in Online Tables 2 and 4 Conen et al.
Swiss-AF Brain Lesions and Cognition in AF Patients 995 definitions and technologies. Nevertheless, the infarct prevalence of 37% in our study seems to be higher than in the general population, where the infarct prevalence was 31%. In addition, most of these infarcts were small (17) . Another study found that the presence of clinically silent infarcts on brain MRI approximately doubled the risk of dementia and led to a steeper decline in cognitive function (18) .
To understand the relationships between AF and cognitive impairment, we specifically assessed imaging markers of vascular disorders known to be asso- Patients with microbleeds have an increased risk of stroke and intracranial hemorrhage (23, 24) . In our study with a high prevalence of anticoagulation use, 22% of participants had microbleeds. This prevalence is similar to that in elderly individuals from the general population (25), or patients with ischemic stroke (26) . Anticoagulation use was not associated with a higher microbleed count, and microbleed count was not associated with cognitive function.
This finding is in agreement with data showing that aspirin and apixaban had a similar impact on the incidence of microbleeds (27) . Currently available data therefore suggest that anticoagulation is safe in most patients with microbleeds, although it remains controversial whether there is a subgroup of patients with a high microbleed burden who should not be started on anticoagulation despite their high stroke risk (28, 29) . 
